The global Cell & Gene Therapy Bioanalytical Testing
Services Market is witnessing significant growth as pharmaceutical and
biotechnology companies accelerate investments in innovative therapies designed
to treat complex and previously untreatable diseases. According to Polaris
Market Research, the market was valued at USD 503.91 million in 2023 and
is projected to grow from USD 540.30 million in 2024 to USD 950.06
million by 2032, registering a CAGR of 7.3% during 2024–2032. The
increasing focus on precision therapies, rising clinical research activities,
and growing demand for specialized analytical support services are key factors
driving market expansion.
The rapid advancement of cell
and gene therapy bioanalytical testing services has transformed the
development landscape for next-generation therapeutics. These services play a
critical role in evaluating the safety, efficacy, potency, and performance of
advanced therapies throughout the drug development lifecycle. As regulatory agencies
implement stringent standards for cell and gene therapy approvals, demand for
specialized bioanalytical testing solutions continues to increase globally.
The broader bioanalytical testing services market is
benefiting from growing investments in research and development activities
across the pharmaceutical and biotechnology sectors. Cell and gene therapies
require highly sophisticated analytical methods to measure therapeutic
effectiveness, biological activity, and treatment outcomes. As the number of
investigational therapies increases, contract research organizations (CROs) and
specialized testing providers are expanding their capabilities to support
evolving industry requirements.
Demand for dedicated cell and gene therapy testing
services is growing rapidly due to the increasing number of therapies being
developed for cancer, rare diseases, neurological disorders, and infectious
diseases. The success of innovative treatments such as CAR-T cell therapies and
gene-editing technologies has encouraged pharmaceutical companies to accelerate
development programs. This trend is creating substantial demand for analytical
testing services that ensure regulatory compliance and product quality
throughout development stages.
One of the fastest-growing segments within the market is the
bioavailability and bioequivalence studies CRO category. According to
Polaris Market Research, the bioavailability and bioequivalence studies segment
is expected to witness the highest growth rate during the forecast period due
to increasing drug innovation activities. These studies are essential for
evaluating therapeutic performance and ensuring consistency across treatment
formulations, making them a critical component of modern drug development
programs.
The increasing importance of pharmacokinetic and
pharmacodynamic testing services is also contributing significantly to
market growth. Pharmacokinetic studies help researchers understand how
therapies are absorbed, distributed, metabolized, and eliminated from the body,
while pharmacodynamic assessments evaluate biological responses to treatment.
Together, these services provide valuable insights that support dosage
optimization, efficacy assessment, and regulatory approval processes.
Government initiatives and funding programs are further
accelerating market development. Numerous countries are investing in advanced
biotechnology infrastructure to support cell and gene therapy research.
Increased funding for clinical research centers, biotechnology laboratories,
and manufacturing facilities is helping expand the ecosystem required for
successful therapy development. These investments are creating new
opportunities for bioanalytical testing service providers worldwide.
From a regional perspective, Asia Pacific held the largest
market share in 2023 and is expected to register the highest growth during the
forecast period. The region is benefiting from increasing investments in
biotechnology research, expanding clinical trial activities, and growing
government support for advanced therapeutic development. Europe is also
expected to experience substantial growth due to rising investments in advanced
therapeutic research and innovation programs.
The product landscape is also evolving rapidly. The cell
therapy segment accounted for the largest market share in 2023 due to
increasing production and development of cell-based therapies targeting
multiple disease indications. As researchers continue exploring new therapeutic
applications, demand for comprehensive analytical testing services is expected
to rise significantly.
As the healthcare industry increasingly embraces advanced
therapies for treating chronic and rare diseases, the Cell
& Gene Therapy Bioanalytical Testing Services Market is expected to
maintain strong growth momentum. The combination of technological innovation,
expanding clinical pipelines, and growing investment in therapeutic development
will continue to drive demand for specialized bioanalytical testing solutions
through 2032.
More Trending Latest Reports By Polaris Market Research:
Next-Generation
Sequencing Market
U.S.
Anti-pollution Nasal Spray Market
Mental
Health Screening Market
Sustainable
Aviation Fuel Market
